Drug Profile
Research programme: gene network therapeutics - Gyre Therapeutics
Latest Information Update: 01 Nov 2023
Price :
$50
*
At a glance
- Originator GNI
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Inflammation; Mycoses
Most Recent Events
- 30 Oct 2023 GNI has merged with Catalyst Biosciences to form Gyre Therapeutics
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Japan
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Japan